[Observations on clinic curative effect of oxymatrine to cure hemorrhagic fever with renal syndrome (HFRS)].
OBJECTIVE
To observe the curative effect of oxymatrine to cure hemorrhagic fever with renal syndrome.


METHODS
Randomly divide 418 patients suffering from hemorrhagic fever with renal syndrome into a treatment group and a control group, use oxymatrine to give an intravenous drip to the patients in the treatment group, one time a day, each time 600 mg, lasting for 7 days as one period of treatment and meanwhile take a traditional equilibrium salt treatment for the patients in the control group. Observe the change of the illness in both groups and occurrence of complications, dynamically test the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin (beta(2)M) of the patients, in the meantime observe the change in magnitude of serum white blood cell medium 15 (IL-15) and soluble intercellular adhesion molecules (sICAM-1).


RESULTS
Shorten the course of the disease of the patients in the oxymatrine treatment group, make an improvement after the recovery and obviously reduce the magnitude of serum urination-regulated protein (THP) and beta(2) microglobulin and show a striking difference in magnitude of serum IL-15 and sICAM-1 after the treatment compared with that of the patients in the control group.


CONCLUSIONS
Oxymatrine has a certainly true curative effect to hemorrhagic fever with renal syndrome and worth of furthering its widespread use in clinics.
Yu
Zhong-qing
ZQ
Department of Infectious Diseases, Heilongjiang Provincial Hospital, Harbin 150036, China.
Wang
Yan
Y
Zeng
Qing-you
QY
Chen
Li-Yan
LY
Wang
Jian-xun
JX
Yang
Jian-xun
JX
Li
Shu-hua
SH
Yang
Bao-shan
BS
D000328:Adult; D000470:Alkaloids / Q000627:therapeutic use*; D005260:Female; D006480:Hemorrhagic Fever with Renal Syndrome / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D019409:Interleukin-15 / Q000097:blood; D008297:Male; D011807:Quinolizines / Q000627:therapeutic use*; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000378:metabolism; D000093842:Matrines
D000470:Alkaloids; D018799:Intercellular Adhesion Molecule-1; D019409:Interleukin-15; D011807:Quinolizines; D001613:beta 2-Microglobulin; C037573:oxymatrine; D000093842:Matrines